| 多西紫杉醇联合健择治疗晚期非小细胞肺癌的系统评价 |
| |
| 引用本文： | 吴银松,王臻. 多西紫杉醇联合健择治疗晚期非小细胞肺癌的系统评价[J]. 医学争鸣, 2004, 25(3): 278-281 |
| |
| 作者姓名： | 吴银松 王臻 |
| |
| 作者单位： | 第四军医大学西京医院骨科,陕西,西安,710033;第四军医大学西京医院骨科,陕西,西安,710033 |
| |
| 摘 要： | 目的：研究健择和多西紫杉醇联合方案治疗晚期非小细胞肺癌(NSCLC)的疗效．方法：应用循证医学系统评价的方法，对目前两药合用的相关临床试验进行系统回顾，并对临床结果进行分析．结果：临床试验表明，两药联合用于晚期NSCLC一线治疗的毒副作用比铂类化疗有所降低，但生存率和生存时间没有明显提高；在曾用铂类和紫杉醇类治疗过的晚期NSCLC中，4项临床试验表明其有较好疗效，且耐受性好．结论：作为晚期NSCLC铂类联合化疗方案的替代，健择和多西紫杉醇联合方案能提高疗效，并降低了毒副反应的发生．
|
| 关 键 词： | 癌 非小细胞肺 多西紫杉醇 健择 循证医学 |
| 文章编号： | 1000-2790(2004)03-0278-04 |
| 修稿时间： | 2003-05-15 |
Chemotherapy of advanced NSCLC by docetaxel combined with gemcitabine:A systematic review |
| |
| WU Yin Song,WANG Zhen. Chemotherapy of advanced NSCLC by docetaxel combined with gemcitabine:A systematic review[J]. Negative, 2004, 25(3): 278-281 |
| |
| Authors: | WU Yin Song WANG Zhen |
| |
| Affiliation: | WU Yin Song,WANG Zhen Department of Orthopedics,Xijing Hospital,Fourth Millitary Medical University,Xi'an 710033,China |
| |
| Abstract: | AIM: To study the efficiency and toxicities of docetaxel gemcitabine combination on advanced non small cell lung cancer (NSCLC). METHODS: A systematic review was made on relevant clinical trials and the results were analyzed. RESULTS: We found that in first line condition, the doublet is superior to platinum chemotherapy by reduced toxicities, but one year survival is not significantly improved; In the second line condition, all 4 clinical trials show both improved survival and better tolerance. CONCLUSION: As an alternative solution to the traditional platinum based chemotherapy of NSCLC, the docetaxel gemcitabine combination has superior efficiency and less toxicities. |
| |
| Keywords: | carcinoma non small cell lung docetaxel gemcitabine evidence based medicine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
